Knollwood Investment Advisory’s Acumen Pharmaceuticals ABOS Stock Holding History

Knollwood Investment Advisory’s Portfolio ABOS Stock Details ABOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.84M	Hold	1,628,510	–	–	0.39%	56
2025 Q4	$3.44M	Hold	1,628,510	–	–	0.32%	65
2025 Q3	$2.78M	Hold	1,628,510	–	–	0.25%	84
2025 Q2	$1.89M	Hold	1,628,510	–	–	0.18%	127
2025 Q1	$1.79M	Hold	1,628,510	–	–	0.2%	126
2024 Q4	$2.8M	Hold	1,628,510	–	–	0.29%	78
2024 Q3	$4.04M	Hold	1,628,510	–	–	0.43%	52
2024 Q2	$3.94M	Hold	1,628,510	–	–	0.44%	51
2024 Q1	$6.6M	Hold	1,628,510	–	–	1.19%	21
2023 Q4	$6.25M	Hold	1,628,510	–	–	1.3%	18
2023 Q3	$6.76M	Sell	1,628,510 -50,000	-3%	-$309K	3.16%	9
2023 Q2	$8.07M	Hold	1,678,510	–	–	2.72%	8
2023 Q1	$6.81M	Hold	1,678,510	–	–	1.32%	12
2022 Q4	$9.06M	Buy	+1,678,510	New	+$11.3M	3.55%	4

Other funds holding ABOS

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return

Knollwood Investment Advisory's ABOS Position: Q1 2026 in Review

Knollwood Investment Advisory held its Acumen Pharmaceuticals (ABOS) position steady in Q1 2026 at 1,628,510 shares worth $3.84M. The position accounts for 0.39% of the portfolio, ranked #56.

Knollwood Investment Advisory first reported a position in ABOS in Q4 2022 and has held it in 14 quarters since. The position peaked at $9.06M in Q4 2022. 84 funds tracked by Wall St. Rank hold ABOS as of Q1 2026.

Knollwood Investment Advisory held 1,628,510 shares of Acumen Pharmaceuticals worth $3.84M as of Q1 2026.
Knollwood Investment Advisory left its Acumen Pharmaceuticals share count unchanged in Q1 2026.
Acumen Pharmaceuticals made up 0.39% of Knollwood Investment Advisory's portfolio in Q1 2026, its #56 holding.
Knollwood Investment Advisory first reported a position in Acumen Pharmaceuticals in Q4 2022 and has held it in 14 quarters since.
Knollwood Investment Advisory's Acumen Pharmaceuticals position peaked at $9.06M in Q4 2022.
84 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q1 2026.

Based on Knollwood Investment Advisory's 13F filing for Q1 2026, filed 14 May 2026.